Magnetar Financial LLC Acquires New Position in Pfizer Inc. $PFE
Magnetar Financial LLC has acquired a new stake in Pfizer Inc. (NYSE:PFE), purchasing 71,927 shares valued at approximately $1.82 million. Other institutional investors, including Vanguard and Northern Trust, have also increased their holdings in Pfizer. The company's stock opened at $24.74, with a market cap of $140.65 billion. Pfizer recently reported a quarterly EPS of $0.78, exceeding estimates, and announced a quarterly dividend of $0.43. Analysts have adjusted price targets for Pfizer, with ratings ranging from "buy" to "neutral."
Magnetar Financial LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 71,927 shares of the biopharmaceutical company's stock, valued at approximately $1,823,000.
- 3 Long-Term Dividend Buys You Can Get for Under $50
A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Northern Trust Corp grew its holdings in Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Pfizer by 3.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after acquiring an additional 1,333,740 shares in the last quarter. Invesco Ltd. grew its holdings in Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after acquiring an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after acquiring an additional 1,846,436 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Stock Up 0.6%
Shares of NYSE:PFE opened at $24.74 on Friday. The firm has a 50 day simple moving average of $24.79 and a 200-day simple moving average of $24.38. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a market capitalization of $140.65 billion, a PE ratio of 13.16, a P/E/G ratio of 0.88 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.
- Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.
Analysts Set New Price Targets
- Top 5 Undervalued Dividend Stocks With Strong Payout Potential
PFE has been the subject of several analyst reports. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. HSBC lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.12.
Read Our Latest Stock Report on PFE
Pfizer Profile
(Free Report)Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
- Five stocks we like better than Pfizer
- Are Penny Stocks a Good Fit for Your Portfolio?
- DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Engines to AI: Cummins’ Surprising Growth Driver
- What Does Downgrade Mean in Investing?
- Smaller Industrials Names Seeing Surging Growth: Here's Why
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Pfizer Right Now?
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
